key: cord-0910798-9p6jk0bu
authors: Pohl, Marie O.; Busnadiego, Idoia; Marrafino, Francesco; Wiedmer, Lars; Hunziker, Annika; Fernbach, Sonja; Omori, Elena; Hale, Benjamin G.; Caflisch, Amedeo; Stertz, Silke
title: Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir
date: 2021-03-22
journal: bioRxiv
DOI: 10.1101/2021.03.19.435806
sha: 079f79a3745a77687275ce99902d011c6fc3abd0
doc_id: 910798
cord_uid: 9p6jk0bu

Rapid repurposing of existing drugs as new therapeutics for COVID-19 has been an important strategy in the management of disease severity during the ongoing SARS-CoV-2 pandemic. Here, we screened by high-throughput docking 6,000 compounds within the DrugBank library for their potential to bind and inhibit the SARS-CoV-2 3CL main protease, a chymotrypsin-like enzyme that is essential for viral replication. For 19 candidate hits, parallel in vitro fluorescence-based protease-inhibition assays and Vero-CCL81 cell-based SARS-CoV-2 replication-inhibition assays were performed. One hit, diclazuril (an investigational anti-protozoal compound), was validated as a SARS-CoV-2 3CL main protease inhibitor in vitro (IC50 value of 29 μM) and modestly inhibited SARS-CoV-2 replication in Vero-CCL81 cells. Another hit, lenvatinib (approved for use in humans as an anti-cancer treatment), could not be validated as a SARS-CoV-2 3CL main protease inhibitor in vitro, but serendipitously exhibited a striking functional synergy with the approved nucleoside analogue remdesivir to inhibit SARS-CoV-2 replication in Vero-CCL81 cells. Lenvatinib is a broadly-acting host receptor tyrosine kinase (RTK) inhibitor, but the synergistic effect with remdesivir was not observed with other approved RTK inhibitors (such as pazopanib or sunitinib), suggesting that the mechanism-of-action is independent of host RTKs. Furthermore, time-of-addition studies revealed that lenvatinib/remdesivir synergy probably targets SARS-CoV-2 replication subsequent to host-cell entry. Our study shows that combining computational and cellular screening is an efficient means to identify existing drugs with repurposing potential as antiviral compounds. Future studies should aim at understanding and optimizing the lenvatinib/remdesivir synergistic mechanism as a therapeutic option. IMPORTANCE Successful repurposing of existing drugs as COVID-19 therapeutics would be a rapid and important means to limit disease severity during the SARS-CoV-2 pandemic. In this study, we used a computational screening approach to identify existing drugs that might inhibit the function of a critical enzyme (the 3CL main protease) encoded by the causative agent of COVID-19, SARS-CoV-2. While we found that diclazuril (an investigational human drug already approved for use in animals) inhibited this viral enzyme in vitro, it only showed modest ability to inhibit SARS-CoV-2 replication in cells. However, our approach serendipitously identified lenvatinib (an anti-cancer drug approved for use in humans) as a potent inhibitor of SARS-CoV-2 replication when combined with the existing approved antiviral drug, remdesivir. Our findings raise the possibility that future studies to understand the molecular mechanisms underlying the lenvatinib/remdesivir synergy could uncover new therapeutic principles for treatment of COVID-19 or similar viral diseases.

ABSTRACT 21 Rapid repurposing of existing drugs as new therapeutics for COVID-19 has been an 22 important strategy in the management of disease severity during the ongoing SARS-CoV-23 2 pandemic. Here, we screened by high-throughput docking 6,000 compounds within the 24 DrugBank library for their potential to bind and inhibit the SARS-CoV-2 3CL main 25 protease, a chymotrypsin-like enzyme that is essential for viral replication. For 19 26 candidate hits, parallel in vitro fluorescence-based protease-inhibition assays and Vero-27 CCL81 cell-based SARS-CoV-2 replication-inhibition assays were performed. One hit, 28 diclazuril (an investigational anti-protozoal compound), was validated as a SARS-CoV-2 29 3CL main protease inhibitor in vitro (IC50 value of 29 µM) and modestly inhibited SARS- 30 CoV-2 replication in Vero-CCL81 cells. Another hit, lenvatinib (approved for use in humans 31 as an anti-cancer treatment), could not be validated as a SARS-CoV-2 3CL main protease 32 inhibitor in vitro, but serendipitously exhibited a striking functional synergy with the 33 approved nucleoside analogue remdesivir to inhibit SARS-CoV-2 replication in Vero-34 CCL81 cells. Lenvatinib is a broadly-acting host receptor tyrosine kinase (RTK) inhibitor, 35 but the synergistic effect with remdesivir was not observed with other approved RTK 36 inhibitors (such as pazopanib or sunitinib), suggesting that the mechanism-of-action is 37 independent of host RTKs. Furthermore, time-of-addition studies revealed that 38 lenvatinib/remdesivir synergy probably targets SARS-CoV-2 replication subsequent to 39 host-cell entry. Our study shows that combining computational and cellular screening is 40 an efficient means to identify existing drugs with repurposing potential as antiviral 41 compounds. Future studies should aim at understanding and optimizing the 42 lenvatinib/remdesivir synergistic mechanism as a therapeutic option. 43 IMPORTANCE 44 Successful repurposing of existing drugs as COVID-19 therapeutics would be a rapid and 45 important means to limit disease severity during the SARS-CoV-2 pandemic. In this study, 46 we used a computational screening approach to identify existing drugs that might inhibit 47 the function of a critical enzyme (the 3CL main protease) encoded by the causative agent 48 of COVID-19, SARS-CoV-2. While we found that diclazuril (an investigational human drug 49 already approved for use in animals) inhibited this viral enzyme in vitro, it only showed 50 modest ability to inhibit SARS-CoV-2 replication in cells. However, our approach 51 serendipitously identified lenvatinib (an anti-cancer drug approved for use in humans) as 52 a potent inhibitor of SARS-CoV-2 replication when combined with the existing approved 53 antiviral drug, remdesivir. Our findings raise the possibility that future studies to 54 understand the molecular mechanisms underlying the lenvatinib/remdesivir synergy could 55 uncover new therapeutic principles for treatment of COVID-19 or similar viral diseases. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entered the human 59 population in late 2019 and rapidly spread around the globe causing a devastating 60 pandemic with significant impacts on human health and the worldwide economy (1, 2). 61 Infection with SARS-CoV-2 results in a respiratory disease, COVID-19, that is mild in most 62 individuals or even asymptomatic. However, in vulnerable patients, in particular in 63 individuals with compromised immune systems, such as the elderly or 64 immunosuppressed, the virus can cause a severe life-threatening pneumonia (2-4). Thus, 65 large efforts have been undertaken to develop vaccines and antiviral drugs for the 66 prevention and treatment of COVID-19. While several vaccines have been developed and 67 licensed at unprecedented speeds, the development of antiviral drugs has not yet been 68 successful (5-8). Remdesivir is the only antiviral drug that is currently approved and used 69 to treat COVID-19 patients in many countries, but its efficacy has been questioned by 70 recent results from a large-scale clinical trial (9, 10). Thus, additional efforts are urgently 71 needed to fill this gap. 72 Early on in the pandemic, drug development approaches focused on the repurposing of 73 drugs approved for other conditions as a means to accelerate the process of bringing drug 74 candidates to market (11, 12). One of the viral drug targets that has gained particular 75 interest is the SARS-CoV-2 protease, 3CL M pro , a chymotrypsin-like protease that cleaves 76 the two polyproteins, pp1a and pp1ab, and is essential for viral replication (13, 14) . 3CL 77 M pro is considered a promising target for drug development as its structure has been 78 solved and there is no homologous human protease (15, 16) . Moreover, protease 79 inhibitors have been developed successfully to treat HIV-1 and hepatitis C virus infections 80 (17, 18) . While several inhibitors of 3CL M pro have already been identified, no drug 81 targeting 3CL M pro has been approved yet (15, (19) (20) (21) (22) . Here, we computationally screened 82 a library of approved drugs for novel 3CL M pro inhibitors. The identified drug candidates 83 were then tested for their antiviral potential in an in vitro 3CL M pro protease-inhibition 84 assay, and in a Vero cell-based virus replication assay using authentic SARS-CoV-2. 85 While two potential inhibitors (diclazuril and ramelteon) identified in silico possessed 86 modest antiviral activity, we found that lenvatinib, an inhibitor of receptor tyrosine kinases 87 such as vascular endothelial growth factor receptors, displayed strong synergistic 88 inhibition of SARS-CoV-2 with the approved drug remdesivir. compounds were purchased for experimental validation (Fig. 1A, B) . 98 An in vitro fluorescence-based protease-inhibition assay with recombinant 3CL M pro 99 protease was employed to measure the potential inhibition of enzymatic activity by each 100 compound. The positive control, GC376, was used as reference compound (22). An IC50 101 (inhibitor concentration that results in 50% reduction of activity with respect to buffer-only 102 solution) value of 316 nM was measured for GC376, which is consistent with a reported 103 value of 190 nM (22). First, single-dose measurements were carried out at 100 µM for 104 each compound (Fig. 1C ). For only two compounds a substantial reduction (> 40% with 105 respect to DMSO-only) of 3CL M pro activity was measured. In follow-up dose-response 106 experiments with these two compounds, diclazuril showed an IC50 of 29 µM, and 107 oprea1_409650 showed an IC50 of 100 µM (Fig. 1D, E) . The binding mode of diclazuril as 108 predicted by docking is shown in Figure 1F . 109 In parallel, we tested the 19 predicted 3CL M pro protease inhibitors for their potential to (1) and (2). The latter placement procedure was used. independent replicates for a given sample was used for hit selection. Compounds 296 associated with a z-score of smaller than -2 were considered as hits for further analysis.

Compounds associated with an average reduction in cell viability of more than 20% 298 relative to the negative control were not considered as hits. 

An interactive web-based dashboard to track COVID-19 400 in real time

A Novel Coronavirus from Patients with Pneumonia in China

Characteristics of and Important Lessons From the 406

COVID-19) Outbreak in China: Summary of a Report of 72314

Cases From the Chinese Center for Disease Control and Prevention

Clinical features of patients infected with 412 2019 novel coronavirus in Wuhan

417 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of 424 the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 432 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials 433 in Brazil, South Africa, and the UK

SARS-CoV-2 vaccines in development

Repurposed Antiviral Drugs for Covid-19 -Interim 443 WHO Solidarity Trial Results

Remdesivir 450 for the Treatment of Covid-19 -Final Report

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound 458 repurposing

Comparative host-coronavirus protein 466 interaction networks reveal pan-viral disease mechanisms

Coronavirus biology and 468 replication: implications for SARS-CoV-2

Coronavirus main 471 proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Crystal structure of SARS-CoV-2 main protease provides a basis for design of 474 improved alpha-ketoamide inhibitors

Crystallographic and electrophilic 480 fragment screening of the SARS-CoV-2 main protease

New antiviral therapies in the management of HCV infection

Fifteen years of HIV Protease 484 Inhibitors: raising the barrier to resistance

Drug 489 repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of 490 SARS-CoV-2 in vitro

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. Antimicrob 494 Agents Chemother 64

Both Boceprevir and GC376 efficaciously inhibit 497 SARS-CoV-2 by targeting its main protease

Feline 500 coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

DrugBank 5.0: a major update to the 505 DrugBank database

Remdesivir Inhibits 510 SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-511 2 RNA Polymerase in Mice

Lenvatinib, a molecule with versatile application: from preclinical evidence to future 514 development in anti-cancer treatment

Lenvatinib: A Promising Molecular Targeted Agent for Multiple 516 Cancers

Structural plasticity of SARS-CoV-2 3CL M(pro) active site 519 cavity revealed by room temperature X-ray crystallography

Efficient electrostatic solvation model for protein-521 fragment docking

Exhaustive docking of 523 molecular fragments with electrostatic solvation

Continuum electrostatic energies of 525 macromolecules in aqueous solutions

All-530 atom empirical potential for molecular modeling and dynamics studies of proteins

Improved treatment of the protein 533 backbone in empirical force fields

CHARMM General Force Field: A 536

Force Field for Drug-Like Molecules Compatible with the CHARMM All-Atom Additive 537 Biological Force Fields

Hydrogen Bonding Penalty upon Ligand Binding

Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility 541 and Restricts SARS-CoV-2

A probability-based approach for the analysis of large-scale 544 RNAi screens